Research graph
References from Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
10.1002/ajh.27216 · 2024 · External reference
Quality of life in myeloproliferative neoplasms: symptoms and management implications
10.1016/j.hoc.2020.12.006 · 2021 · External reference
The essential thrombocythemia in 2020: what we know and where we still have to dig deep
10.1177/2634853520978210 · 2020 · External reference
Essential thrombocythemia and post‐essential thrombocythemia myelofibrosis: updates on diagnosis, clinical aspects, and management
10.1093/labmed/lmac074 · 2023 · External reference
The myeloproliferative neoplasm symptom assessment form (MPN‐SAF): international prospective validation and reliability trial in 402 patients
10.1182/blood-2011-01-328955 · 2011 · External reference
Essential thrombocythemia: a review
10.1001/jama.2024.25349 · 2025 · External reference
Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
10.1080/16078454.2022.2105582 · 2022 · External reference
Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis
10.1007/s00277-019-03654-6 · 2019 · External reference
Long‐term follow‐up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy
10.1002/ajh.21360 · 2009 · External reference
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea
10.3109/10428194.2014.893310 · 2014 · External reference
A review of hydroxyurea‐related cutaneous adverse events
10.1080/14740338.2021.1945032 · 2021 · External reference
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide
10.1002/ajh.25294 · 2019 · External reference
Pegylated interferon alfa‐2a in patients with essential thrombocythaemia or polycythaemia vera: a post‐hoc, median 83 month follow‐up of an open‐label, phase 2 trial
10.1016/s2352-3026(17)30030-3 · 2017 · External reference
Interferon alpha therapy in essential thrombocythemia and polycythemia vera‐a systematic review and meta‐analysis
10.1038/s41375-020-01020-4 · 2021 · External reference
Interferons in the treatment of myeloproliferative neoplasms
10.1177/20406207241229588 · 2024 · External reference
Interferon‐beta gene therapy inhibits tumor formation and causes regression of established tumors in immune‐deficient mice
10.1073/pnas.95.24.14411 · 1998 · External reference
Direct evidence that IFN‐beta functions as a tumor‐suppressor protein
10.1089/10799900260442511 · 2002 · External reference
An anti‐cancer surveillance by the interplay between interferon‐beta and retinoblastoma protein RB1
10.3389/fonc.2023.1173467 · 2023 · External reference
A plain language summary about a cell cycle‐based, new surveillance mechanism against cancer
10.1080/14796694.2024.2402649 · 2024 · External reference
Interferon‐alpha for treating polycythemia vera yields improved myelofibrosis‐free and overall survival
10.1038/s41375-021-01183-8 · 2021 · External reference
Event‐free survival in patients with polycythemia vera treated with ropeginterferon alfa‐2b versus best available treatment
10.1038/s41375-023-02008-6 · 2023 · External reference
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
10.1038/s41375-025-02545-2 · 2025 · External reference
A randomized phase 3 trial of interferon‐α vs hydroxyurea in polycythemia vera and essential thrombocythemia
10.1182/blood.2021012743 · 2022 · External reference
Pegylated interferon alfa‐2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
10.1182/blood.2019000428 · 2019 · External reference
Ropeginterferon alfa‐2b in hydroxyurea‐intolerant or hydroxyurea‐refractory essential thrombocythaemia (SURPASS ET): a multicentre, open‐label, randomised, active‐controlled, phase 3 study
10.1016/s2352-3026(25)00264-9 · 2025 · External reference
SURPASS‐ET: phase III study of ropeginterferon alfa‐2b versus anagrelide as second‐line therapy in essential thrombocythemia
10.2217/fon-2022-0596 · 2022 · External reference
Unresolved reference
External reference
Exposure‐efficacy and exposure‐safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera
10.1111/bcp.16043 · 2024 · External reference
Population pharmacokinetics‐pharmacodynamics and exposure‐response of ropeginterferon alfa‐2b in Chinese and Japanese patients with polycythemia vera
10.1002/prp2.70109 · 2025 · External reference
Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F
10.1200/jco.2015.61.6474 · 2015 · External reference
Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial
10.1200/jco.22.01935 · 2023 · External reference
JAK2 V617F allele burden in polycythemia vera: burden of proof
10.1182/blood.2022017697 · 2023 · External reference
Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)
10.1002/hem3.70137 · 2025 · External reference
Ropeginterferon alfa‐2b versus standard therapy for polycythaemia vera (PROUD‐PV and CONTINUATION‐PV): a randomised, non‐inferiority, phase 3 trial and its extension study
10.1016/s2352-3026(19)30236-4 · 2020 · External reference
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
10.1002/ajh.21593 · 2010 · External reference
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analyses from the REVEAL study
10.1182/blood.2023020232 · 2024 · External reference
Risk factors for arterial and venous thrombosis in WHO‐defined essential thrombocythemia: an international study of 891 patients
10.1182/blood-2011-02-339002 · 2011 · External reference
Novel long‐acting ropeginterferon alfa‐2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial
10.1111/bcp.15176 · 2022 · External reference
Pharmacokinetics and pharmacodynamics of novel long‐acting ropeginterferon alfa‐2b in healthy Chinese subjects
10.1007/s12325-021-01863-y · 2021 · External reference
Pharmacokinetics and pharmacodynamics of ropeginterferon alfa‐2b in healthy Japanese and Caucasian subjects after single subcutaneous administration
10.1007/s40261-021-01026-5 · 2021 · External reference
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa‐2b‐njft in patients with essential thrombocythemia in the US and Canada: EXCEED‐ET trial
10.3389/fmed.2025.1548590 · 2025 · External reference
Population pharmacokinetics of ropeginterferon alfa‐2b: a comparison between healthy Caucasian and Chinese subjects
10.3389/fphar.2021.673492 · 2021 · External reference
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia
10.1007/s12185-014-1721-9 · 2015 · External reference
The impact of JAK2V617F mutation on Philadelphia‐negative myeloproliferative neoplasms
2022 · External reference
General pharmacokinetic model for drugs exhibiting target‐mediated drug disposition
10.1023/a:1014414520282 · 2001 · External reference
Interspecies scaling of receptor‐mediated pharmacokinetics and pharmacodynamics of type I interferons
10.1007/s11095-010-0098-6 · 2010 · External reference
